Search results for: Vaccines
Filter search results
Previews of Forthcoming Publications
27 July 2011
…One on access to drugs and vaccines in developing countries and the other on measuring value with pharmacoeconomics. OHE is making available as Occasional Papers drafts of two important chapters…
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
…need for new treatments for multi-drug resistance (MDR) TB, and for better diagnostics and vaccines. In 2020, CGD and OHE set out a blueprint for a novel financing mechanism to…
Immunisation for Everyone – The Polio Experience
1 September 1979
…effective and safe immunising techniques. There are today around 80 vaccines which protect against a wide range of infectious diseases. The purpose of this OHE briefing is to highlight key…
Childhood Vaccination: Current Controversies
1 July 1984
…and Koch in Germany established the science of bacteriology, thus paving the way for the development of vaccines. The latter process has continued into the twentieth century and has been…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…discounting to gene therapies could delay or prevent patients from accessing potentially transformative therapies. The discounting challenge is not unique to gene therapies. Other health technologies like cell therapies, vaccines,…
Stuart Carroll
30 August 2023
Stuart Carroll is a senior health economist and epidemiologist with over 18 years of experience, specialising in infectious diseases and vaccines, market access, health technology appraisal, public health, and public…
Employer Costs from Respiratory Infections
16 December 2024
…vaccines, hygiene, and social distancing, could yield big returns for businesses. With many working adults excluded from NHS-provided respiratory vaccines, employer-led vaccination programs could bridge the gap and drive productivity…
OHE Annual Lecture Webinar 2020: How Should the World Pay for a COVID-19 Vaccine?
24 June 2020, 11:00pm
…company’s up-front investment was for nothing? We have seen moves in a number of countries to restrict patent rights for COVID vaccines and therapies; but perceived intellectual property (IP) risk…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
…the US price (policies roughly equivalent to linking markets through price transparency) increases deadweight loss for drugs and vaccines by over 50%. They also find that a monopolist manufacturer of…